Stevanato Group S.p.A. (NYSE:STVN) Given Average Recommendation of “Moderate Buy” by Analysts

Stevanato Group S.p.A. (NYSE:STVN) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company.

Several equities research analysts have issued reports on STVN shares. UBS Group dropped their target price on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research report on Friday, March 7th. Morgan Stanley reiterated an “equal weight” rating and issued a $23.00 target price (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Bank of America raised their price target on Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Wolfe Research began coverage on Stevanato Group in a report on Friday, December 13th. They issued an “outperform” rating and a $28.00 price objective for the company. Finally, William Blair reissued an “outperform” rating on shares of Stevanato Group in a report on Friday, March 7th.

Institutional Trading of Stevanato Group

Institutional investors have recently added to or reduced their stakes in the business. Conestoga Capital Advisors LLC lifted its stake in shares of Stevanato Group by 5.3% in the 4th quarter. Conestoga Capital Advisors LLC now owns 8,082,996 shares of the company’s stock valued at $176,128,000 after acquiring an additional 407,086 shares during the last quarter. TimesSquare Capital Management LLC increased its stake in Stevanato Group by 114.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company’s stock worth $71,657,000 after purchasing an additional 1,756,100 shares during the period. Wellington Management Group LLP lifted its position in Stevanato Group by 4.5% in the third quarter. Wellington Management Group LLP now owns 2,693,588 shares of the company’s stock valued at $53,872,000 after purchasing an additional 115,050 shares during the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of Stevanato Group by 28.7% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company’s stock valued at $51,333,000 after purchasing an additional 524,989 shares during the period. Finally, Bamco Inc. NY grew its holdings in shares of Stevanato Group by 7.9% in the fourth quarter. Bamco Inc. NY now owns 1,818,181 shares of the company’s stock worth $39,618,000 after purchasing an additional 133,000 shares during the last quarter.

Stevanato Group Stock Down 4.9 %

Shares of NYSE:STVN opened at €21.26 ($22.86) on Friday. The firm has a fifty day moving average price of €21.03 and a two-hundred day moving average price of €20.59. The company has a market cap of $6.44 billion, a price-to-earnings ratio of 45.23, a PEG ratio of 7.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group has a one year low of €16.56 ($17.81) and a one year high of €33.49 ($36.01).

Stevanato Group (NYSE:STVN) last released its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting the consensus estimate of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The firm had revenue of €352.68 million for the quarter, compared to analysts’ expectations of €346.26 million. Analysts anticipate that Stevanato Group will post 0.5 EPS for the current fiscal year.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.